Risk factors for relapse in human immunodeficiency virus type 1 infected adults with pulmonary tuberculosis

International Journal of Tuberculosis and Lung Disease

Volumn 1, Issue 5, 1997, Pages 446-453

  Johnson, J L ^a,b,c   Okwera, A ^c,d   Vjecha, M J ^a,c   Byekwaso, F ^c,d   Nakibali, J ^c,d   Nyole, S ^c,d   Milberg, J ^c   Aisu, T ^c,e   Whalen, C C ^a,c   Mugerwa, R D ^a,c   Ellner, J J ^a,c  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MAKERERE UNIVERSITY   (Uganda)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d Natl TB and Leprosy Contr Prog   (Uganda)

^e Uganda TB Investigations   (Uganda)

Author keywords

HIV; Relapse; Rifampicin; Thiacetazone; Tuberculosis

Indexed keywords

RIFAMPICIN; THIOACETAZONE; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; AIDS RELATED COMPLEX; ARTICLE; CASE CONTROL STUDY; CLINICAL TRIAL; COMPARATIVE STUDY; DEVELOPING COUNTRY; DRUG COMBINATION; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; LUNG; LUNG TUBERCULOSIS; MALE; MICROBIOLOGY; MIDDLE AGED; MORTALITY; PATIENT COMPLIANCE; PROSPECTIVE STUDY; RADIOGRAPHY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RISK FACTOR; SPUTUM; STATISTICAL MODEL; SURVIVAL RATE; UGANDA;

ADOLESCENT; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTITUBERCULAR AGENTS; CASE-CONTROL STUDIES; DEVELOPING COUNTRIES; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HIV-1; HUMANS; LOGISTIC MODELS; LUNG; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PROSPECTIVE STUDIES; RECURRENCE; RIFAMPIN; RISK FACTORS; SPUTUM; SURVIVAL RATE; THIOACETAZONE; TUBERCULOSIS, PULMONARY; UGANDA;

EID: 0031240979     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Aber V R, Nurm A J. Factors affecting relapse following short- course chemotherapy. Bull Int Union Tuberc 1978; 53: 260- 267.
2. Tripathy S P. Relapse in tuberculosis. Indian J Tuberc 1981; 28: 45-57.
3. Hawken M, Nunn P, Gathua S, et al. Increased recurrence of tuberculosis in HIV-1 infected patients in Kenya. Lancet 1993; 342: 332-337
4. Perriens J H, St. Louis M E, Mukadi Y, et al. Pulmonary tuberculosis in HIV-infectcd patients in Zaire. A controlled trial of treatment for either 6 or 12 months. N Engl J Med 1995; 332: 779-784.
5. Hopewell P, Cynamon M, Starke J, Iseman M, O'Brien R. Evaluation of new anti-infective drugs for the treatment and prevention of tuberculosis. Clin Infect Dis 1992; 15 (Suppl 1): S282- S295.
6. Okwera A, Whalen C, Byekwaso F, et al. Randomised trial of thiacetazone and rifampicin-containing regimens for pulmonary tuberculosis in HIV-infected Ugandans. Lancet 1994; 344: 1323-1328.
7. International Union Against Tuberculosis and Lung Disease. Technical Guide for Sputum Examination for Tuberculosis by Direct Microscopy. Bull Int Union Tuberc 1986; 61 (Suppl 2): 1-16.
8. Canetti G, Fox W, Khomenko A, et al. Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes. Bull World Health Organ 1969; 41: 21-43.
9. National Tuberculosis and Respiratory Disease Association. Classification of pulmonary tuberculosis. In: Diagnostic Standards and Classification of Tuberculosis. New York: National Tuberculosis and Respiratory Disease Association, 1969: pp. 68-76.
10. Oyama T, Tatsuoka M. Prediction of relapse in pulmonary tuberculosis. An application of discriminant analysis. Am Rev Tuberc 1956; 73: 472-484.
11. Idigbe E O, Nasidi A, John E K O. Treatment for pulmonary tuberculosis in HIV-infected patients in Nigeria. VIII International Conf on AIDS. Florence, July 1992 [abstract POB 3084].
12. Perriens J H, Colebunders R L, Karahunga C, et al. Increased mortality and tuberculosis treatment failure rate among human immunodeficiency virus (HIV) seropositive compared with HIV seronegative patients with pulmonary tuberculosis treated with "standard" chemotherapy in Kinshasa, Zaire. Am Rev Respir Dis 1991; 144: 750-755.
13. Ormerod L P, Prescott R J. Inter-relations between relapses, drug regimens and compliance with treatment in tuberculosis. Respir Med 1991; 85: 239-242.
14. Kopanoff D E, Snider D E Jr, Johnson M. Recurrent tuberculosis: why do patients develop disease again? A United States Public Health Service Cooperative Survey. Am J Public Health 1988; 78: 30-33.
15. Pulido F, Peña J M, Rubio R, et al. Relapse of tuberculosis after treatment in human immunodeficiency virus-infected patients. Arch Intern Med 1997; 157: 227-232.
16. Small P M, Schecter G F, Goodman P C, Sande M A, Chaisson R E, Hopewell P C. Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. N Engl J Med 1991; 324: 289-294.
17. Lahart C, Breaux K, Risser J, Nickson R. Relapse in TB/HIV patients during long-term follow-up [abstract I103]. In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, D.C.: American Society for Microbiology, 1995.
18. East African/British Medical Research Council Third Thiacetazone Investigation. Isoniazid with thiacetazone (thioacetazone) in the treatment of pulmonary tuberculosis in East Africa. Third investigation: The effect of an initial streptomycin supplement. Tubercle 1966; 47: 1-32.
19. East African/British Medical Research Council Fifth Thiacetazone Investigation. Isoniazid with thiacetazone (thioacetazone) in the treatment of pulmonary tuberculosis in East Africa. Fifth investigation. Tubercle 1970; 51: 123-151.
20. Mitchison D A. Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at two months. Am Rev Respir Dis 1993; 147: 1062-1063.
21. Soriano E J, Mallolas J, Gatell J M, et al. Characteristics of tuberculosis in HIV-infected patients: a case-control study. AIDS 1988; 2: 429-432.
22. Theuer C P, Hopewell P C, Elias D, et al. Human immunodeficiency virus infection in tuberculosis patients. J Infect Dis 1990; 162: 8-12.
23. Perronne C, Ghoubontni A, Leport C, Salmon-Céron D, Bricaire F, Vildé J L. Should pulmonary tuberculosis be an AIDS- defining diagnosis in patients infected with HIV? Tubercle Lung Dis 1992; 73: 39-44.
24. Schürmann D, Bergmann F, Jautzke G U, Fehrenbach F J, Mauch H, Ruf B. Acute and long-term efficacy of antituberculosis treatment in HIV-seropositive patients with tuberculosis: a study of 36 cases. J Infection 1993; 26: 45-54.
25. Kassim S, Sassan-Morokro M, Ackah A, et al. Two-year followup of persons with HIV-1- and HIV-2-associated pulmonary tuberculosis treated with short-course chemotherapy in West Africa. AIDS 1995; 9: 1185-1191.
26. Jones B E, Otaya M, Antoniskis D, et al. A prospective evaluation of antituberculosis therapy in patients with human immunodeficiency virus infection. Am J Respir Crit Care Med 1994; 150: 1499-1502.
27. Blazes D L, Alwood K, Keruly J C, Moore-Rice K, Moore R D, Chaisson R E. Effectiveness of short-course treatment of HIV- related tuberculosis [abstract]. J Invest Med 1995; 43 (Suppl 2): 369A.
28. Kim T C, Blackman R S, Heatwole K M, Kim T, Rochester D F. Acid-fast bacilli in sputum smears of patient with pulmonary tuberculosis: prevalence and significance of negative smears pretreatment and positive smears post-treatment. Am Rev Respir Dis 1984; 129: 264-268.
29. Alwood K, Keruly J, Moore-Rice K, Stanton D L, Chaulk C P, Chaisson R E. Effectiveness of supervised, intermittent therapy for tuberculosis in HIV-infected patients. AIDS 1994; 8: 1103-1108.
30. Chaisson R E, Schecter G F, Theuer C P, Rutherford G W, Echenberg D F, Hopewell P C. Tuberculosis in patients with the acquired immunodeficiency syndrome. Clinical features, response to therapy, and survival. Am Rev Respir Dis 1987; 136: 570-574.
31. Murray C J L, DeJonghe E, Chum H J, Nyangulu D S, Salomao A, Styblo K. Cost effectiveness of chemotherapy for pulmonary tuberculosis in three sub-Saharan African countries. Lancet 1991; 338: 1305-1308.
32. Wilkinson D. High-compliance tuberculosis treatment programme in a rural community. Lancet 1994; 343: 647-648.
33. China Tuberculosis Control Collaboration. Results of directly observed short-course chemotherapy in 112 842 Chinese patients with smear-positive tuberculosis. Lancet 1996; 347: 358-362.
34. Nunn P, Kibuga D, Gathua S, et al. Cutaneous hypersensitivity reactions due to thiacetazone in HIV-1 seropositive patients treated for tuberculosis. Lancet 1991; 337: 627-630.
35. Nunn P, Brindle R, Carpenter L, et al. Cohort study of human immunodeficiency virus infection in patients with tuberculosis in Nairobi, Kenya. Analysis of early (6-month) mortality. Am Rev Respir Dis 1992; 146: 849-854.
36. Godfrey-Faussett P, Githui W, Batchelor B, et al. Recurrence of HIV-related tuberculosis in an endemic area may be due to relapse or reinfection. Tubercle Lung Dis 1994; 75: 199-202.